IP Library › Granted Patent US 12,358,971
Granted Patent B2
US 12,358,971 · App. 18/392,147 · Granted Jul 15, 2025

Arena virus monoclonal antibodies and uses

Inventors: Luis M. Branco (Germantown, MD); Robert F. Garry (New Orleans, LA); James E. Robinson (New Orleans, LA); Erica O. Saphire (La Jolla, CA); Kathryn M. Hastie (La Jolla, CA); Thomas W. Geisbert (Albany, TX)
Assignees: The Administrators of the Tulane Educational Fund; The Boad of Regents of the University of Texas System; The Scripps Resesrch Institute; Zalgen Labs, LLC
C07K16/10A61P31/14C07K2317/21C07K2317/31C07K2317/33C07K2317/565C12N2760/10011
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,358,971
App. No.
18/392,147
Granted
Jul 15, 2025
Kind
B2
Abstract

Disclosed herein are compositions comprising recombinant arenavirus monoclonal antibodies and antigen-binding fragments thereof, as well as therapeutic methods using the antibodies. In some embodiments, the antibodies provide pan-arenavirus protection against a number of arenavirus types and strains.

Claims (26)

1. An antigen-binding composition comprising a combination of three recombinant monoclonal neutralizing antibodies or neutralizing antigen-binding antibody fragments thereof, which are specific to Lassa virus glycoprotein, wherein the composition comprises:

a recombinant human monoclonal antibody or an antigen-binding antibody fragment thereof comprising a V H CDR1 of SEQ ID NO: 83, a V H CDR2 of SEQ ID NO: 84, a V H CDR3 of SEQ ID NO: 85, a V L CDR1 of SEQ ID NO: 125, a V L CDR2 of sequence Gly Ala Ser, and a V L CDR3 of SEQ ID NO: 126;

a recombinant human monoclonal antibody or an antigen-binding antibody fragment thereof comprising a V H CDR1 of SEQ ID NO: 92, a V H CDR2 of SEQ ID NO: 93, a V H CDR3 of SEQ ID NO: 94, a V L CDR1 of SEQ ID NO: 131, a V L CDR2 of sequence Glu Val Ser, and a V L CDR3 of SEQ ID NO: 132; and

a recombinant human monoclonal antibody or an antigen-binding antibody fragment thereof comprising a V H CDR1 of SEQ ID NO: 98, a V H CDR2 of SEQ ID NO: 99, a V H CDR3 of SEQ ID NO: 100, a V L CDR1 of SEQ ID NO: 135, a V L CDR2 of sequence Gly Ala Ser, and a V L CDR3 of SEQ ID NO: 136.

2. The composition of claim 1 , wherein each antigen-binding antibody fragment is selected from the group consisting of a Fab, a Fab′, and a F(ab′) 2 fragment.

3. A pharmaceutical composition for treating a Lassa virus or a lymphocytic choriomeningitis virus infection comprising the composition of claim 1 and a pharmaceutically acceptable carrier.

4. The composition of claim 1 wherein the composition comprises:

a recombinant human monoclonal antibody or an antigen-binding antibody fragment thereof comprising a V H of SEQ ID NO: 39 and a V L of SEQ ID NO: 55;

a recombinant human monoclonal antibody or an antigen-binding antibody fragment thereof comprising a V H of SEQ ID NO: 42 and a V L of SEQ ID NO: 58; and

a recombinant human monoclonal antibody or an antigen-binding antibody fragment thereof comprising a V H of SEQ ID NO: 44 and a V L of SEQ ID NO: 60.

5. The composition of claim 4 , wherein each antigen-binding antibody fragment is selected from the group consisting of a Fab, a Fab′, and a F(ab′) 2 fragment.

6. A pharmaceutical composition for treating infection by a Lassa virus or a lymphocytic choriomeningitis virus comprising the composition of claim 4 and a pharmaceutically acceptable carrier.

7. An antigen-binding composition comprising a recombinant human monoclonal neutralizing antibody or a neutralizing antigen-binding antibody fragment thereof, which is specific for Lassa virus glycoprotein; the antibody or antibody fragment thereof comprising a V H CDR1 of SEQ ID NO: 83, a V H CDR2 of SEQ ID NO: 84, a V H CDR3 of SEQ ID NO: 85, a V L CDR1 of SEQ ID NO: 125, a V L CDR2 of sequence Gly Ala Ser, and a V L CDR3 of SEQ ID NO: 126.

8. The composition of claim 7 , wherein the antigen-binding antibody fragment is selected from the group consisting of a Fab, a Fab′, and a F(ab′) 2 fragment.

9. The composition of claim 7 wherein the composition comprises a recombinant human monoclonal antibody or an antigen-binding antibody fragment thereof comprising a V H of SEQ ID NO: 39 and a V L of SEQ ID NO: 55.

10. A pharmaceutical composition for treating infection by a Lassa virus or a lymphocytic choriomeningitis virus comprising the composition of claim 7 and a pharmaceutically acceptable carrier.

11. An antigen-binding composition comprising a recombinant human monoclonal neutralizing antibody or a neutralizing antigen-binding antibody fragment thereof, which is specific for Lassa virus glycoprotein; the antibody or antibody fragment thereof comprising a V H CDR1 of SEQ ID NO: 92, a V H CDR2 of SEQ ID NO: 93, a V H CDR3 of SEQ ID NO: 94, a V L CDR1 of SEQ ID NO: 131, a V L CDR2 of sequence Glu Val Ser, and a V L CDR3 of SEQ ID NO: 132.

12. The composition of claim 11 , wherein the antigen-binding antibody fragment is selected from the group consisting of a Fab, a Fab′, and a F(ab′) 2 fragment.

13. The composition of claim 11 , wherein the composition comprises a recombinant human monoclonal antibody or an antigen-binding antibody fragment thereof comprising a V H of SEQ ID NO: 42 and a V L of SEQ ID NO: 58.

14. A pharmaceutical composition for treating infection by a Lassa virus or a lymphocytic choriomeningitis virus comprising the composition of claim 11 and a pharmaceutically acceptable carrier.

15. A method of treating or preventing a Lassa virus infection or a lymphocytic choriomeningitis virus infection in a subject comprising administering the composition of claim 1 to the subject.

16. A method of treating or preventing a Lassa virus infection or a lymphocytic choriomeningitis virus infection in a subject comprising administering the composition of claim 4 to the subject.

17. A method of treating or preventing a Lassa virus infection or a lymphocytic choriomeningitis virus infection in a subject comprising administering the composition of claim 7 to the subject.

18. A method of treating or preventing a Lassa virus infection or a lymphocytic choriomeningitis virus infection in a subject comprising administering the composition of claim 9 to the subject.

19. A method of treating or preventing a Lassa virus infection in a subject comprising administering the composition of claim 11 to the subject.

20. A method of treating or preventing a Lassa virus infection in a subject comprising administering the composition of claim 13 to the subject.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2024
From: GARRY, ROBERT F.; ROBINSON, JAMES E.
To: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
Reel/Frame 069640/0785 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2024
From: SAPHIRE, ERICA O.; HASTIE, KATHRYN M.
To: THE SCRIPPS RESEARCH INSTITUTE
Reel/Frame 069640/0951 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2024
From: GEISBERT, THOMAS W.
To: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
Reel/Frame 069641/0258 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2024
From: BRANCO, LUIS M.
To: ZALGEN LABS, LLC
Reel/Frame 069641/0426 →
Continuity (4)
Division 17520338 · Nov 5, 2021
Division 16466544
Provisional Application 62430225 · Dec 5, 2016
Related Publication 20240352095A1 · Oct 24, 2024
References Cited (93)
US 4816567A · Cabilly et al. · 1989 [cited by applicant]
US 5219740A · Miller et al. · 1993 [cited by applicant]
US 5422120A · van der Meij et al. · 1995 [cited by applicant]
US 5530101A · Queen et al. · 1996 [cited by applicant]
US 5565332A · Hoogenboom et al. · 1996 [cited by applicant]
US 5580717A · Dower et al. · 1996 [cited by applicant]
US 5580859A · Felgner et al. · 1996 [cited by applicant]
US 5585362A · Wilson et al. · 1996 [cited by applicant]
US 5693762A · Queen et al. · 1997 [cited by applicant]
US 5733743A · Johnson et al. · 1998 [cited by applicant]
US 5807715A · Morrison et al. · 1998 [cited by applicant]
US 5866692A · Shitara et al. · 1999 [cited by applicant]
US 6180370B1 · Queen et al. · 2001 [cited by applicant]
US 6265150B1 · Terstappen et al. · 2001 [cited by applicant]
US 6331415B1 · Cabilly et al. · 2001 [cited by applicant]
US 6376471B1 · Lawrence, III et al. · 2002 [cited by applicant]
US 6413942B1 · Felgner et al. · 2002 [cited by applicant]
US 6436908B1 · Koch et al. · 2002 [cited by applicant]
US 20140271580A1 · Garry et al. · 2014 [cited by applicant]
CN 105296507A · 2016 [cited by applicant]
CN 105548539A · 2016 [cited by applicant]
WO 20080124176A2 · 2008 [cited by applicant]
Xiang, J., et al., 1991, Modification in framework region 1 results in a decreased affinity of chimeric anti-TAG72 antibody, Mol. Immunol. 28(1/2):141-148. [cited by examiner]
Xiang, J., et al., 1995, Framework residues 71 and 93 of the chimeric B72.3 antibody are major determinants of the conformation of heavy-chain hypervariable loops, J. Mol. Biol.253:385-390. [cited by examiner]
Sela-Culang, I., Oct. 2013, The structural basis of antibody-antigen recognition, Front. Immunol. 4, Article 302, pp. 1-13. [cited by examiner]
Andersen, K.G. et al., Clinical Sequencing Uncovers Origins and Evolution of Lassa Virus, Cell 162, 738-750 (2015). [cited by applicant]
Auperin, D. D. et al., Nucleotide Sequence of the Glycoprotein Gene and Intergenic Region of the Lassa Virus S Genome RNA, Virology 154, 155-167 (1986). [cited by applicant]
Beyer, W.R. et al., Endoproteolytic Processing of the Lymphocytic Choriomeningitis Virus Glycoprotein by the Subtilase SKI-1/S1P, Journal of Virology 77 (5), 2866-2872 (2003). [cited by applicant]
Branco, L.M. et al., Lassa Virus-Like Particles Displaying All Major Immunological Virology Determinants as a Vaccine Candidate for Lassa Hemorrhagic Fever, Virology Journal 7 (279), 1-19 (2010). [cited by applicant]
Branco, L.M. et al., Emerging Trends in Lassa Fever: Redefining The Role of Immunoglobulin M and Inflammation in Diagnosing Acute Infection, Virology Journal 8 (478), 1-15 (2011). [cited by applicant]
Buchmeier, M.J. et al., Monoclonal Antibodies to Lymphocytic Choriomeningitis Virus React With Pathogenic Arenaviruses, Nature 288, 486-487 (1980). [cited by applicant]
Buchmeier, M.J. et al., Arenaviruses: Protein Structure and Function, Current Topics in Microbiology and Immunology, 288, 159-173 (2002). [cited by applicant]
Buck, D.W. et al., Monoclonal Antibodies Specific for Cell Culture Mycoplasmas, In Vitro 18 (4), 377-381 (1982). [cited by applicant]
Burnette, W.N., Western Blotting: Electrophoretic Transfer of Proteins From Sodium Dodecyl Sulfate—Polyacrylamide Gels to Unmodified Nitrocellulose and Radiographic Detection With Antibody and Radioiodinated Protein A, … [cited by applicant]
Chiou, H.C. et al., In Vivo Gene Therapy Via Receptor-Mediated DNA Delivery, Gene Therapeutics: Methods and Applications of Direct Gene Transfer 141-156, Birkhauser Boston (1994). [cited by applicant]
Clegg, J.C.S et al., Structural and Cell-Associated Proteins of Lassa Virus, Journal General Virology 64, 1127-1136 (1983). [cited by applicant]
Curiel, D.T. et al., High-Efficiency Gene Transfer Mediated by Adenovirus Coupled to DNA-Polylysine Complexes, Human Gene Therapy 3, 147-154 (1992). [cited by applicant]
Dayhoff, M.O. et al., A Model of Evolutionary Change in Proteins, Atlas of Protein Sequence and Structure, 345-358 (1978). [cited by applicant]
Eichler, R. et al., Lassa Virus Glycoprotein Signal Peptide Displays a Novel Topology With an Extended Endoplasmic Reticulum Luminal Region, The Journal of Biological Chemistry 279 (13), 12293-12299 (2004). [cited by applicant]
Eichler, R. et al., Identification of Lassa Virus Glycoprotein Signal Peptide as a Trans-Acting Maturation Factor, EMBO Reports 4 (11), 1084-1088 (2003). [cited by applicant]
Eichler, R. et al., Signal Peptide of Lassa Virus Glycoprotein GP-C Exhibits an Unusual Length, FEBS Letters 538, 203-206 (2003). [cited by applicant]
Elagoz, A. et al., Biosynthesis and Cellular Trafficking of the Convertase SKI-1-S1P, The Journal of Biological Chemistry 277 (13), 11265-11275 (2002). [cited by applicant]
Findeis, M.A. et al., Targeted Delivery of DNA for Gene Therapy Via Receptors, Trends Biotechnology 11, 202-205 (1993). [cited by applicant]
Grove, J.N. et al., Capacity Building Permitting Comprehensive Monitoring of a Severe Case of Lassa Hemorrhagic Fever in Sierra Leone With a Positive Outcome: Case Report, Virology Journal 8 (314), 1-14 (2011). [cited by applicant]
Hartnett, J.N. et al., Current and Emerging Strategies for the Diagnosis, Prevention and Treatment of Lassa Fever, Future Virology 10 (5), 559-584 (2015). [cited by applicant]
Higgins, D.G. et al., Fast and Sensitive Multiple Sequence Alignments on a Microcomputer, Cabios Communications 5 (2), 151-153 (1989). [cited by applicant]
Hufert, F.T. et al., Epitope Mapping of the Lassa Virus Nucleoprotein Using Monoclonal Anti-Nucleocapsid Antibodies, Arch Virology 106, 201-212 (1989). [cited by applicant]
Johnson, K.S. et al., Human Antibody Engineering, Current Opinion in Structural Biology 3, 564-571 (1993). [cited by applicant]
Kohler, G. et al., Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity, Nature 256, 495-497 (1975). [cited by applicant]
Lenz, O. et al., Identification of a Novel Consensus Sequence at the Cleavage Site of the Lassa Virus Glycoprotein, Journal of Virology 74 (23), 11418-11421 (2000). [cited by applicant]
Lonberg, N. et al., Human Antibodies From Transgenic Mice, International Reviews of Immunology 13, 65-93 (1995). [cited by applicant]
Lukashevich, I.S. et al., Lassa Virus Activity in Guinea: Distribution of Human Antiviral Antibody Defined Using Enzyme-Linked Immunosorbent Assay With Recombinant Antigen, Journal of Medical Virology 40, 210-217 (1993). [cited by applicant]
McCafferty, J. et al., Phage Antibodies: Filamentous Phage Displaying Antibody Variable Domains, Nature 348, 552-554 (1990). [cited by applicant]
McCormick, J.B. et al., Lassa Fever, Current Topics in Microbiology and Immunology 262, 75-109 (2002) . [cited by applicant]
Meulen, J.T. et al., Characterization of Human CD4+ T-Cell Clones Recognizing Conserved and Variable Epitopes of the Lassa Virus Nucleoprotein, Journal of Virology 74 (5), 2186-2192 (2000). [cited by applicant]
Meulen, J.T. et al., Detection of Lassa Virus Antinucleoprotein Immunoglobulin G (IgG) and IgM Antibodies by a Simple Recombinant Immunoblot Assay for Field Use, Journal of Clinical Microbiology 36 (11), 3143-3148 (1998… [cited by applicant]
Myers, E.W. et al., Optimal Alignments in Linear Space, CABIOS 4 (1) 11-17 (1988). [cited by applicant]
Peeters, K. et al., Production of Antibodies and Antibody Fragments in Plants, Vaccine 19 2756-2761 (2001). [cited by applicant]
Philip, R. et al., Efficient and Sustained Gene Expression in Primary T Lymphocytes and Primary and Cultured Tumor Cells Mediated by Adeno-Associated Virus Plasmid DNA Complexed to Cationic Liposomes, Molecular and Cell… [cited by applicant]
Pollock, D.P. et al., Transgenic Milk as a Method for the Production of Recombinant Antibodies, Journal of Immunological Methods 231, 147-157 (1999). [cited by applicant]
Robinson, D.F., Comparison of Labeled Trees With Valency Three, Journal of Combinatorial Theory 11, 105-119 (1971). [cited by applicant]
Ruo, S.L. et al., Antigenic Relatedness Between Arenaviruses Defined at the Epitope Level by Monoclonal Antibodies, Journal of General Virology 72, 549-555 (1991). [cited by applicant]
Saitou, N. et al., The Neighbor-Joining Method: A New Method for Reconstructing Phylogenetic Trees, Molecular Biology Evol. 4 (4):406-425 (1987). [cited by applicant]
Sanchez, A. et al., Junin Virus Monoclonal Antibodies: Characterization and Cross-Reactivity With Other Arenaviruses, Journal General Virology 70, 1125-1132 (1989). [cited by applicant]
Shaffer, J.G. et al., Lassa Fever in Post-Conflict Sierra Leone, PLOS Neglected Tropical Diseases 8 (3), e2748, 1-12 (2014). [cited by applicant]
Spiropoulou, C.F. et al., New World Arenavirus Clade C, but Not Clade A and B Viruses, Utilizes a-Dystroglycan as its Major Receptor, Journal of Virology 76 (10), 5140-5146 (2002). [cited by applicant]
Wilbur, W.J. et al., Rapid Similarity Searches of Nucleic Acid and Protein Data Banks, PNAS 80, 726-730 (1983). [cited by applicant]
Winter, G. et al., Making Antibodies by Phage Display Technology, Annual Review Immunology 12, 433-455 (1994). [cited by applicant]
Woffendin, C. et al., Nonviral and Viral Delivery of a Human Immunodeficiency Virus Protective Gene Into Primary Human T Cells, PNAS 91, 11581-11585 (1994). [cited by applicant]
Wu, G.Y. et al., Receptor-Mediated Gene Delivery in Vivo, Partial Correction of Genetic Analbuminemia in Nagase Rats, The Journal of Biological Chemistry 266 (22), 14338-14342 (1991). [cited by applicant]
Wu, G.Y. et al., Receptor-Mediated Gene Delivery and Expression in Vivo, The Journal of Biological Chemistry 263(29), 14621-14624 (1988). [cited by applicant]
Wu, C.H., et al., Targeting Genes: Delivery and Persistent Expression of a Foreign Gene Driven by Mammalian Regulatory Elements in Vivo, The Journal of Biological Chemistry 264 (29), 16985-16987 (1989). [cited by applicant]
Wu, G.Y. et al., Incorporation of Adenovirus Into a Ligand-based DNA Carrier System Results in Retention of Original Receptor-Mediated Specificity and Enhances Targeted Gene Expression, The Journal of Biological Chemist… [cited by applicant]
York, J. et al., Genetic Analysis of Heptad-Repeat Regions in the G2 Fusion Subunit of the Junin Arenavirus Envelope Glycoprotein, Virology 343, 267-274 (2005). [cited by applicant]
York, J. et al., The Signal Peptide of the Junin Arenavirus Envelope Glycoprotein is Myristoylated and Forms an Essential Subunit of the Mature G1-G2 Complex, Journal of Virology 78 (19), 10783-10792 (2004). [cited by applicant]
Both, L. et al., Monoclonal Antibodies for Prophylactic and Therapeutic Use Against Viral Infections, Vaccine 31, 1553-1559 (2013). [cited by applicant]
Branco, L.M. et al., Shedding of Soluble Glycoprotein 1 Detected During Acute Lassa Virus Infection in Human Subjects, Virology Journal 7 (1), Biomed Central, London, GB, 306 (2010). [cited by applicant]
Buchmeier, M.J. et al., Monoclonal Antibodies to Lymphocytic Choriomeningitis and Pichinide Viruses: Generation, Characterization, and Cross-Reactivity With Other Arenaviruses, Virology 113 (1), 73-85 (1981). [cited by applicant]
Cross, R.W. et al., Antibody Therapy for Lassa Fever, Current Opin. Virology 37, 97-104 (2019). [cited by applicant]
Cross, R.W. et al., Treatment of Lassa Virus Infection in Outbred Guinea Pigs With First-in-Class Human Monoclonal Antibodies, Antiviral Research 133, 218-222 (2016). [cited by applicant]
Fisher-Hoch, S.P. et al., Effective Vaccine for Lassa Fever, Journal of Virology 74 (15), 6777-6783 (2000). [cited by applicant]
Hastie, K.M. et al., Structural Basis for Antibody-Mediated Neutralization of Lassa Virus, Science 356 (6341), 923-928 (2017). [cited by applicant]
Lukashevich, I.S., Advanced Vaccine Candidates for Lassa Fever, Viruses 4, 2514-2557 (2012). [cited by applicant]
Mahmutovic, S. et al., Molecular Basis for Antibody-Mediated Neutralization of New World Hemorrhagic Fever Mammarenaviruses, Cell Host & Microbe 18 (6), 705-713 (2015). [cited by applicant]
Mire, C.E., Human-Monoclonal-Antibody Therapy Protects Nonhuman Primates Against Advanced Lassa Fever, Nature Medicine 23 (10) 1146-1149 (2017). [cited by applicant]
Robinson, J.E. et al., Most Neutralizing Human Monoclonal Antibodies Target Novel Epitopes Requiring Both Lassa Virus Glycoprotein Subunits, Nature Communications 7 (11544), 1-14 (2016). [cited by applicant]
Robinson, J.E. et al., Supplementary Information for Most Neutralizing Human Monoclonal Antibodies Target Novel Epitopes Requiring Both Lassa Virus Glycoprotein Subunits, Nature Communications 7, 1-13 (2016). [cited by applicant]
Zapata, J.C. et al., Improving the Breadth of the Host's Immune Response to Lassa Virus, Pathogens 7, 84:doi:10.3390/pathogens7040084, 1-18 (2018). [cited by applicant]
Zenke, M., et al., Receptor-Mediated Endocytosis of Transferrin-Polycation Conjugates: An Efficient Way to Introduce DNA Into Hematopoietic Cells, PNAS 87, 3655-3659 (1990). [cited by applicant]
Xiang, J, et al., Framework Residues 71 and 93 of the Chimeric B72.3 Antibody are Major Determinants of the Conformation of Heavy-chain Hypervariable Loops, J. Mol. Biol. 253:385-390 (1995). [cited by applicant]
Xiang, J., et al., Modification in Framework Region I Results in a Decreased Affinity of Chimeric Anti-TAG72 Antibody, Mol. Immunol. 28 (1/2):141-148 (1991). [cited by applicant]
Sela-Culang, I., et al., The Structural Basis of Antibody-Antigen Recognition, Front. Immunol. 4 (Article 302), 1-13 (2013). [cited by applicant]
Robinson, J. E., et al., Most Neutralizing Human Monoclonal Antibodies Target Novel Epitopes Requiring Both Lassa Virus Glycoprotein Subunits, Nat. Comm. 7:11544, pp. 1-14 (2016). [cited by applicant]